Literature DB >> 10098870

Differential involvement of central and peripheral norepinephrine in the central lipopolysaccharide-induced interleukin-6 responses in mice.

D K Song1, Y B Im, J S Jung, H W Suh, S O Huh, S W Park, M B Wie, Y H Kim.   

Abstract

Intracerebroventricular injection of lipopolysaccharide (LPS) induces a marked increase in circulating interleukin (IL)-6 levels and in IL-6 mRNA expression in brain and peripheral organs. Recently, it was reported that intraperitoneal administration of alpha-adrenoceptor antagonists inhibits centrally injected LPS-induced increases in plasma IL-6 levels, suggesting the involvement of the norepinephrine (NE) system in the central LPS-induced IL-6 response. However, the localization (either central or peripheral) of NE involvement in the central LPS-induced IL-6 response has not been characterized. In the present study, mice were pretreated with 6-hydroxydopamine (6-OHDA) administered intracerebroventricularly or intraperitoneally to deplete central or peripheral stores of NE, respectively. Intracerebroventricular LPS (50 ng/mouse) markedly increased plasma IL-6 levels and IL-6 mRNA expression in choroid plexus, hypothalamus, pituitary, adrenals, heart, liver, spleen, and lymph nodes, but with minimal effect in lung, kidney, and testis, as revealed by RT-PCR. Pretreatment with intracerebroventricular 6-OHDA (50 microg/mouse) decreased the LPS-induced plasma IL-6 levels by 39% and the LPS-induced IL-6 mRNA expression in liver, spleen, and lymph nodes, but not in choroid plexus, hypothalamus, pituitary, adrenals, and heart. Pretreatment with intraperitoneal 6-OHDA (100 mg/kg) decreased the LPS-induced plasma IL-6 levels by 36% and the LPS-induced IL-6 mRNA expression in all the peripheral organs displaying increased IL-6 mRNA. Central LPS-induced increase in plasma corticosterone levels was decreased slightly by central but not by peripheral NE depletion. These results suggest that central NE and peripheral NE are differentially involved in the central LPS-induced IL-6 mRNA expression in peripheral organs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098870     DOI: 10.1046/j.1471-4159.1999.721625.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Lipopolysaccharide-induced leptin release is neurally controlled.

Authors:  C A Mastronardi; W H Yu; V K Srivastava; W L Dees; S M McCann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

2.  Central injection of nitric oxide synthase inhibitors increases peripheral interleukin-6 and serum amyloid A: involvement of adrenaline from adrenal medulla.

Authors:  D K Song; Y B Im; J S Jung; J J Yan; S O Huh; H W Suh; Y H Kim
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Increased production of inflammatory cytokines in mild cognitive impairment.

Authors:  Shino Magaki; Claudius Mueller; Cindy Dickson; Wolff Kirsch
Journal:  Exp Gerontol       Date:  2006-11-07       Impact factor: 4.032

4.  Corticotropin-releasing hormone regulates IL-6 expression during inflammation.

Authors:  M Venihaki; P Dikkes; A Carrigan; K P Karalis
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

5.  Adrenergic regulation of clock gene expression in mouse liver.

Authors:  Hideyuki Terazono; Tatsushi Mutoh; Shun Yamaguchi; Masaki Kobayashi; Masashi Akiyama; Rhyuta Udo; Shigehiro Ohdo; Hitoshi Okamura; Shigenobu Shibata
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-16       Impact factor: 11.205

6.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.

Authors:  K S Rommelfanger; G L Edwards; K G Freeman; L C Liles; G W Miller; D Weinshenker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

7.  alpha1-Adrenergic receptor stimulates interleukin-6 expression and secretion through both mRNA stability and transcriptional regulation: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB.

Authors:  Dianne M Perez; Robert S Papay; Ting Shi
Journal:  Mol Pharmacol       Date:  2009-04-10       Impact factor: 4.436

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.